Addex Therapeutics Ltd (ADXN)
NASDAQ: ADXN · Real-Time Price · USD
3.060
-0.440 (-12.57%)
At close: Nov 18, 2026, 4:00 PM EST
3.220
+0.160 (5.23%)
Pre-market: Nov 19, 2026, 8:10 AM EST
Addex Therapeutics Employees
Addex Therapeutics had 3 employees as of December 31, 2025. The number of employees increased by 1 or 50.00% compared to the previous year.
Employees
3
Change (1Y)
1
Growth (1Y)
50.00%
Revenue / Employee
$34,269
Profits / Employee
-$2,834,421
Market Cap
6.38M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 3 | 1 | 50.00% |
| Dec 31, 2024 | 2 | -21 | -91.30% |
| Dec 31, 2023 | 23 | -1 | -4.17% |
| Dec 31, 2022 | 24 | -2 | -7.69% |
| Dec 31, 2021 | 26 | -1 | -3.70% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vistagen Therapeutics | 41 |
| BioLineRx | 24 |
| IN8bio | 20 |
| Moleculin Biotech | 17 |
| CalciMedica | 15 |
| Ensysce Biosciences | 10 |
| MetaVia | 8 |
| Immuron | 8 |
ADXN News
- 6 days ago - Addex Therapeutics Ltd Spin-out Neurosterix Closes $105 Million Series B Financing - Nasdaq
- 7 days ago - Addex Shares Surge As Neurosterix Closes $105M Financing To Advance Schizophrenia Program - Nasdaq
- 7 days ago - Addex Spin-out Neurosterix Closes $105 Million Series B Financing - GlobeNewsWire
- 21 days ago - Addex Therapeutics Ltd Increases Issued Share Capital to Create Treasury Shares - Nasdaq
- 21 days ago - ADDEX INCREASES ISSUED SHARE CAPITAL TO CREATE TREASURY SHARES - GlobeNewsWire
- 6 weeks ago - Addex Spin-Out Neurosterix Takes NTX-253 Closer To Phase 2 Schizophrenia Trial - Nasdaq
- 6 weeks ago - Addex Therapeutics spin-out company completes NTX-253 clinical studies - TheFly
- 6 weeks ago - Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia - GlobeNewsWire